Coryfin

Quick links to important sections

Coryfin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coryfin

Classification and Identity as a Fixed-Dose Combination

Coryfin is classified as a fixed-dose combination drug that functions as an Oral/Throat Preparation for local application. This specific combination is recognized for providing dual symptomatic action, distinguishing it from single-agent formulations often found in the market. The medicine is manufactured as a transmucosal tablet (lozenge), which necessitates the bucco-pharyngeal route of administration, a form specifically chosen to maximize the contact time of the active ingredients with the irritated tissues in the mouth and throat. This product’s identity confirms its role within the category of Anti-cough and Cold Preparations suitable for general use when localized throat discomfort occurs.

Composition, Action, and General Soothing Principle

The primary action of the lozenge is driven by its two main components. Menglytate is a synthetic menthol derivative that acts to provide a localized cooling effect. This action helps to quiet the feeling of soreness or scratchiness that often leads to discomfort. The second component, Sodium Ascorbate, is a derived salt of Vitamin C (L-Ascorbic acid). Its inclusion provides antioxidant support to the local mucous membranes. The result for the patient is that this medicine helps ease discomfort by providing a distinct, localized counterirritation and soothing sensation.

The strategic choice of the lozenge format and the inclusion of Sodium Ascorbate highlight the product's focus on sustained, supportive symptomatic comfort, setting it apart from quick-dissolving products or simple sugar cough drops.

What side effects are possible with Coryfin?

Possible Side Effects and Safety Information

Coryfin (Menglytate and Sodium Ascorbate lozenge) has an official safety profile defined by local reactions and specific restrictions related to the menthol derivative content, as stated in regulatory documents.


Frequency and Adverse Reactions

The most frequently observed adverse events are generally categorized as Hypersensitivity Phenomena, which may involve a reaction of sensitization or localized irritation at the administration site. Regulatory data classifies these events as occurring in rare cases.

Safety Constraints and Population-Specific Risks

The official labeling documents the most critical safety concerns in specific patient groups, driven by the risk associated with the menthol component, a terpene derivative:

  • Pediatric Contraindications: The lozenge is explicitly contraindicated in children under 30 months of age. It is also contraindicated in any child with a documented history of epilepsy or febrile convulsions. Exceeding recommended exposure in these populations may carry a risk of convulsions, a serious adverse reaction.
  • Duration Limit: The medicine must not be prolonged for more than three days. This restriction is explicitly imposed to mitigate the risk of the systemic accumulation of the terpene derivatives.
  • Interaction Restriction: Official safety notes dictate that Coryfin must not be used concomitantly with other products—medicinal or cosmetic—that also contain terpene derivatives, regardless of the route of administration.
  • Hypersensitivity: Use is contraindicated in individuals with a known allergy or hypersensitivity to the active substances or any excipients.

This structure ensures that the primary focus of the regulatory safety information is on strict adherence to the defined age and exposure limits to manage the low-frequency but serious neurological risk tied to the terpene derivative.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Coryfin overdose focuses on the risks associated with massive or high-dose ingestion of the active components. Documented overdose presentations may include gastrointestinal effects such as nausea, vomiting, diarrhea, and abdominal pain, as well as systemic symptoms like headache.

Regulatory documentation defines overdose as a condition that can lead to severe, life-threatening outcomes affecting the renal, central nervous, and metabolic systems. These critical risks include nephrolithiasis, oxalate nephropathy, and metabolic acidosis, with potential for CNS damage. Patients with pre-existing renal impairment are noted as having a documented increased risk for these severe manifestations.

The official regulatory requirement is that any accidental or suspected over-ingestion mandates immediate external medical intervention. The explicit emergency action, as stated in government labeling, is to seek medical help or contact a Poison Control Center right away. Treatment is defined as symptomatic and supportive, as the regulatory profile does not specify a chemical antidote.

Therapeutic Uses of Coryfin

What Coryfin Treats: Main Uses and Benefits

Coryfin (Menglytate and Sodium Ascorbate lozenge) is focused on localized symptomatic support for the upper respiratory tract. The lozenge is commonly used to help provide symptomatic relief for minor throat issues, a therapeutic approach consistent with official drug labels for this class.

Therapeutic Domains and Benefits

The primary therapeutic domains include easing the discomfort of a scratchy throat sensation, addressing a pronounced throat tickle, and managing minor pharyngeal soreness. The medicine is relevant for easing an irritation-associated cough and supporting vocal comfort during episodes of hoarseness. This short-term symptomatic assistance may assist with addressing symptom clusters that may become temporarily disruptive. The application is relevant when short-term symptomatic assistance is appropriate for managing discomfort associated with irritative states in the throat.

Coryfin is often applied in scenarios where irritation is caused by exposure to dry indoor air, seasonal irritants, or excessive talking (vocal strain). Providing this supportive relief may assist with maintaining functional stability, contributing to easing the overall symptom load.

Quick Fact: Relief for Localized Irritation

Quick Fact: Relief for Localized Irritation

  • May assist with managing symptoms related to inflammatory or irritative states in the throat.
  • Is relevant for easing symptoms that interfere with daily comfort, such as throat soreness or tickle.

Regulatory References

  1. NIH DailyMed Drug Label for Menthol Lozenges

Eligibility and Restrictions for Use

Who Can and Cannot Use Coryfin?

This section outlines the official population eligibility and non-eligibility rules for Coryfin (Menglytate and Sodium Ascorbate lozenge) as defined by authoritative governmental regulatory documents.


Eligibility Scope

Category Regulatory Status
Populations Contraindicated Individuals with a known hypersensitivity to Ascorbic Acid, Menglytate, or any other ingredient. Also contraindicated for patients with hemochromatosis or a history of recurrent renal calculi (kidney stones), due to the Ascorbate component.
Age-Related Restrictions Not recommended for children under the minimum specified age threshold (typically four to six years) due to regulatory warnings concerning the lozenge dosage form and its ingredients. Use in infants under two years is strongly advised against.
Conditional Use Required Use in pregnant and breastfeeding individuals is restricted; consultation is necessary before use, especially when the dose exceeds the established Recommended Dietary Allowance (RDA). Caution is also required for patients on a sodium-restricted diet or those undergoing certain cancer treatments.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions for Coryfin (Menglytate and Sodium Ascorbate) are formally documented in regulatory labeling based on the systemic pharmacokinetic and pharmacodynamic properties of the Sodium Ascorbate component. The official profile details specific interaction patterns, while no mandatory timing-based co-administration rules are stipulated in prescribing information.

Documented Pharmacodynamic and Exposure Interactions

Interacting Substance Official Regulatory Outcome
Antibiotics (e.g., Erythromycin, Lincomycin) The Ascorbate component may cause a decrease in the activities of certain anti-infective medicines.
Bleomycin Ascorbic acid is explicitly documented to inactivate Bleomycin in vitro.
Amphetamine pH-sensitive drugs like Amphetamine may experience decreased serum concentration due to altered renal excretion caused by urine acidification.
Elemental Iron Supplements The intake of the Ascorbate component is noted to increase the absorption of iron from the intestines.
Oral Contraceptives / Smoking These substances are associated with a decreased plasma concentration of the Ascorbate component.
Aspirin Concomitant use may interfere with the absorption of ascorbic acid.

Population and Procedural Constraints

Regulatory documents specify that patients with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency are identified as a population group with an increased risk for severe hemolysis during treatment with the Ascorbate component. Furthermore, the presence of ascorbic acid may interfere with laboratory tests that rely on oxidation-reduction reactions, necessitating awareness during procedures such as certain blood and urine glucose testing.

Mechanism of Action

The pharmacological action of Coryfin involves a simultaneous, two-part mechanism focused on peripheral sensory signaling and the localized biochemical environment of the mucosal tissue.


Modulating Peripheral Sensory Perception

The primary mechanism involves Menglytate acting as a direct agonist on the Transient Receptor Potential Melastatin 8 ( TRPM8) ion channel found on nerve endings in the oropharynx. This molecular interaction initiates a signal perceived as cooling, which physically modulates the transmission of nociceptive input by altering the signal sequence on the peripheral sensory nerve fiber.


Localized Biochemical Regulation

The formulation includes Sodium Ascorbate, which functions via an antioxidant mechanism. Its core action is to scavenge and neutralize Reactive Oxygen Species ( ROS) and free radicals present in the local tissue. This chemical activity reduces the concentration of Reactive Oxygen Species, which limits the impact of free radical activity on local cell structures.

Dosage and Administration Information

How to Use Coryfin: Official Administration Guidelines

Coryfin is a fixed-dose combination product formulated as a transmucosal tablet (lozenge), which is administered via the oral/bucco-pharyngeal route for local application. This usage method requires the lozenge to slowly dissolve in the mouth to facilitate the intended action. It is essential not to chew or swallow the tablet.


Official Dosing Regimens

The standard adult regimen for Coryfin is strictly defined by the lozenge strength and is intended for short-term symptomatic support only. The total duration of use must not exceed three consecutive days.

Strength Dosing Frequency Maximum Daily Dose
Low Strength (2.8 mg Menglytate) One lozenge every 1 to 2 hours 8 lozenges
High Strength (6.5 mg Menglytate) One lozenge every 2 to 3 hours 6 lozenges

Population-Specific Instructions

The official administration rules include specific modifications for pediatric use. For children over 30 months of age, the dose for the low strength formulation is reduced to one lozenge every 4 hours. The maximum daily intake for this population must not exceed 4 lozenges per day. Administration is not authorized for children under 30 months of age. Users must adhere strictly to the established maximum daily dose limits for their respective age group and strength.

Recent Clinical Evidence

Research evidence / Overview of studies for Coryfin


Evidence for Acute Non-Specific Throat Discomfort

Research has focused on the lozenge format for use in conditions characterized by acute episodes of minor throat irritation, such as scratchiness or generalized soreness. Studies have been conducted during periods of increased symptom activity, utilizing short-term, randomized controlled trials (RCTs). These trials were used in research exploring how symptoms change over time. Specifically, researchers monitored how scores on subjective scales for throat pain and the feeling of soreness were reported over short time intervals.

Studies explored populations of adults presenting with typical, mild-to-moderate, non-specific throat complaints. Studies report how symptoms evolved in the observed populations, tracking data that show patterns related to temporary relief in the immediate hours following the lozenge's application compared to inactive controls. Findings help contextualize how patients reported their experience during these short, focused study periods. The evidence contributes to the broader evidence landscape of symptom patterns related to lozenges containing counterirritant compounds.


The Role of the Fixed-Dose Combination in Research

Research has sought to evaluate the lozenge's fixed-dose combination. The product was studied for outcomes capturing phases of heightened symptom activity, with the intent of examining the local action provided by the menthol derivative (Menglytate) combined with the supportive salt (Sodium Ascorbate). The lozenge combination was studied in randomized controlled trials against placebo controls, and researchers tracked measurements of patient-reported outcomes describing perceived discomfort. While the evidence for symptomatic relief from counterirritant lozenges is established, specific findings related to this particular combination was observed in some studies, but evidence quality varies across studies.


What is Still Uncertain About Coryfin Research

Research exploring short-term symptom changes typically involves follow-up periods that are quite limited, often ranging from single-dose immediate assessment up to only a few days of continuous use. Long-term effects are not fully established, as the follow-up durations were limited. Furthermore, data for certain groups remain insufficient, with limited information from research focusing specifically on young children (under 12 years old), pregnant individuals, or those with underlying significant chronic health conditions. Evidence is also limited on the separate and specific contribution of the Sodium Ascorbate component when applied locally via the lozenge.

Key Studies & References

  1. Menthol (Halls, Ricola, and others): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - Summary of Menthol OTC Monograph
  2. Label: FREEGELLS COUGH DROPS MENTHOL 80CT- menthol lozenge - DailyMed - NIH (for Menthol OTC Monograph/Warnings)
  3. Preventing and Treating Common Cold | CDC (Guideline for general symptomatic relief, lozenges, and use in children)
  4. Sore throats suck. Do throat lozenges help at all? (Review of local anaesthetic/counterirritant lozenge RCTs)

Frequently Asked Questions (FAQ)

Common questions about Coryfin (FAQ)


Q: What is the main ingredient in Coryfin?

Official product information states that Coryfin is a fixed-dose combination product, meaning it has two active components. These are Menglytate, a derivative of menthol, and Sodium Ascorbate, which is a salt of Vitamin C. It is defined by the combined action of both components.


Q: Is Coryfin a pain reliever or is it for something else?

Coryfin is intended to provide symptomatic comfort and soothing for throat irritation. Its main mechanism of action works by modulating nociceptive input, which refers to the peripheral nerve signals that cause the feeling of soreness or pain. It is therefore focused on relieving the discomfort associated with irritation.


Q: Why do some people refer to Coryfin as a decongestant?

According to official regulatory classification, Coryfin is defined as an Oral/Throat Preparation intended for local application in the mouth and throat (bucco-pharyngeal area). Its mechanism of action targets local discomfort and is not intended to function as a nasal decongestant.


Q: How quickly can someone expect Coryfin to start working?

Because Coryfin is a lozenge designed to slowly dissolve in the mouth, the local effect begins as the active ingredients contact the irritated tissues. Studies indicate that patients may experience temporary relief patterns in the immediate hours following the lozenge's application.


Q: What is the typical length of time Coryfin stays in the body?

Official patient information does not usually specify a precise half-life for this product. However, regulatory documents stress that use should not exceed three consecutive days. This restriction is imposed to prevent the systemic accumulation of the menthol derivatives, which could lead to adverse effects.


Q: Is Coryfin available over the counter or does it require a prescription?

The regulatory status of Coryfin, determining whether it is available over the counter or requires a prescription, depends on the local medicinal product classification in each country. This status can vary between different national medicine agencies.


Q: Can Coryfin be taken by someone with high blood pressure?

Specific contraindications related to high blood pressure are not detailed in the official safety warnings. However, patients on a sodium-restricted diet may note that the product contains Sodium Ascorbate.


Q: How does Coryfin compare to other common medications for similar uses?

Regulatory classification defines Coryfin as a fixed-dose combination product intended for local use. This identity is based on its dual symptomatic action, which pairs the localized cooling effect from the menthol derivative with the antioxidant support provided by the Sodium Ascorbate component.


Q: Can Coryfin be taken alongside multivitamins or supplements?

Official labeling includes known interactions with specific substances, noting that the Ascorbate component can increase the absorption of elemental iron supplements. It is descriptive that the general properties of Vitamin C warrant consideration when the product is used alongside other vitamins or supplements.


Q: Does Coryfin interact with blood thinners?

Regulatory documents include an interaction with Aspirin, which may interfere with the absorption of the ascorbic acid component. As Aspirin affects blood clotting, the documented interaction with Aspirin warrants professional awareness regarding potential interactions with other blood thinners.


Q: What does the FDA or other regulatory body say about Coryfin's safety profile?

The official safety profile is defined by strict adherence to duration and age limits established by regulatory documents. These constraints are in place to mitigate the low, documented risk associated with the systemic accumulation of terpene derivatives, which can carry a risk of convulsions if limits are exceeded.


Q: What happens if someone accidentally takes more Coryfin than intended?

Taking more than the recommended dose, particularly in children, carries an increased risk of serious adverse reactions. This risk is due to the menthol derivative, which can cause violent and involuntary muscle contractions, or convulsions, if exposure limits are exceeded.


Q: Is Coryfin known to cause stomach upset?

The most frequently observed adverse events listed in official labeling are localized reactions, such as hypersensitivity phenomena or irritation at the administration site. Systemic gastrointestinal effects, such as general stomach upset, are not listed among these commonly reported reactions.


Q: Are there specific food or drink interactions to know about when using Coryfin?

Official prescribing information focuses on drug-drug and drug-substance interactions. It does not stipulate mandatory timing-based co-administration rules with specific food or drink.


Q: Is it normal to feel a tingling sensation after taking Coryfin?

The official mechanism of action explains the sensation. The main component activates specific ion channels on the nerve endings in the throat, creating a counterirritant signal that is perceived by the user as a cooling or tingling feeling.


Q: Why is Coryfin sometimes used in combination with other drugs?

The product is designed as a fixed-dose combination to deliver dual symptomatic action. This approach combines the immediate, localized cooling effect from the menthol derivative with the supportive, localized antioxidant function of the Sodium Ascorbate component.


Q: Is Coryfin effective for non-respiratory issues?

Official documents state that the approved use is strictly for the symptomatic relief of acute episodes of minor throat irritation, such as soreness or scratchiness. The administration method is via the bucco-pharyngeal route, meaning its action is localized to the mouth and throat.


Q: What is the official patient information leaflet called for Coryfin?

The official document containing patient information is known by various names, such as the Patient Information Leaflet, the Package Insert, or Consumer Medical Information. The specific title used often depends on the national regulatory body that approved the drug.


Q: Is it okay to take Coryfin while using herbal remedies?

The official safety notes document a restriction against the simultaneous use of Coryfin with any other product, medicinal or cosmetic, that also contains terpene derivatives. This is a restriction intended to prevent overexposure to the menthol derivative component.

How should Coryfin be stored and disposed of?

How to Store and Dispose of Coryfin?

The official storage and disposal guidelines for Coryfin lozenges are defined by strict regulatory standards to ensure product stability and safety.

Storage Conditions

Coryfin must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product requires protection from excessive heat, moisture, and direct light to prevent degradation of its active components. It is mandatory to keep the medicine in its original container and ensure the packaging is kept tightly closed.

Child Safety and Disposal

Consistent with all regulatory labeling, Coryfin must be stored out of the sight and reach of children. For disposal, unused or expired lozenges should be discarded according to local regulations. The product is not classified as hazardous waste, and generally, should not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coryfin found in:

A-Z Index: